AbbVie Drug Reduces Skin-Disease Lesions in Late-Stage Trial
AbbVie said its experimental drug lutikizumab significantly reduced inflammatory lumps and abscesses in patients with a chronic skin disease, meeting the main goal of a late-stage study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.